权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular understanding of leukemic bone marrow cytokine-Ras signals and metabolic dependence

白血病骨髓细胞因子-Ras 信号和代谢依赖性的分子理解

基本信息

批准号：
10545014
负责人：
JEROEN ROOSE
金额：
$ 37.59万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-01 至 2026-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10545014
关键词：
20 year old Acute Lymphocytic Leukemia Acute T Cell Leukemia Bar Codes Biochemical Biological Bone Diseases Bone Marrow Bone Marrow Diseases Bone Marrow Stem Cell CCL21 gene CRISPR interference Cancer Etiology Cell Line Cells Cellular Metabolic Process Cessation of life Characteristics Childhood Childhood Acute Lymphocytic Leukemia Childhood Precursor T Lymphoblastic Leukemia Clinic Clinical Combined Modality Therapy DNA Sequence Alteration Data Dependence Development Epithelial Cells FRAP1 gene Flow Cytometry Genetic Goals Grant Guanosine Triphosphate Hematopoiesis Hematopoietic Hematopoietic stem cells Heterogeneity Immune In Vitro KRASG12D Lead Leukemic Cell Malignant Neoplasms Measurement Measures Metabolic Metabolism Methods Mission Modeling Molecular Mus Mutation Nutrient Oncogenic Pathway interactions Patients Persons Phenotype Phosphatidylinositide 3-Kinase Inhibitor Phosphatidylinositols Phosphotransferases Point Mutation Progress Reports Proto-Oncogene Proteins c-akt RALGDS gene Research Research Personnel Resistance Resolution Role Sampling Signal Transduction T-Cell Leukemia Testing Time Tubulin United States National Institutes of Health Vincristine acute T-cell lymphoblastic leukemia cell biobank cancer type chemotherapy cytokine design experience fitness genome-wide high dimensionality in vivo in vivo evaluation inhibitor inhibitor therapy innovation insight interest kinase inhibitor leukemia mouse model new combination therapies novel overexpression pre-clinical precision medicine preclinical trial programs ral Guanine Nucleotide Exchange Factor small molecule inhibitor stem stem cells synergism technology platform

项目摘要

PROJECT SUMMARY/ABSTRACT Childhood Acute Lymphoblastic Leukemia (ALL) is a disease of the bone marrow with expansion of immature cells and treated with non-specific chemotherapy. ALL remains one of the leading causes of cancer death in persons <20 years old. The developmental origin of T cell ALL (T-ALL) is and profoundly impacts the clinic. Genetic mutations pointed aberrant Ras signals with causal role in 50% of T-ALL, but how such aberrant signals impact developmental trajectories in T-ALL is not known. Similarly, it is by and large unknown how to effectively inhibit aberrant Ras signals. During 1R01CA187318 we uncovered a new molecular paradigm in Ras signaling; Oncogenic Ras mutations (KRasG12D) and overexpression of the Ras activator RasGRP1 drive two very distinctive leukemic Ras signals. In the progress report with our new RoLoRiG/Mx1CRE mouse model, we show that these two aberrant Ras signals both induce abnormal hematopoiesis, but with opposing stem cell features. Capitalizing on our quantitative, multiplex flow cytometry platform we determined that Ras and RasGRP1 frequently connect to PI3K (phosphoinositide 3-kinase)-AKT/mTOR signaling in T-ALL. Next, we performed four extensive synthetic lethality screens with PI3K inhibitors to identify effective combination therapy in T-ALL. We confirmed ten predicted combination therapies with small molecule inhibitors and the PI3K inhibitor GDC0941 with tubulin inhibitor Vincristine yields broad synergy in five cancer types and in our preclinical mouse trials in vivo. The screens predict many metabolic targets, which remained unexplored. Our renewal focuses on understanding the connection between aberrant Ras-PI3K signals and cell metabolism with the goal of resolving the developmental origin of T-ALL and testing new combination therapies. We will determine the connections between Ras-PI3K signals and cell metabolism in our panel of 10 T-ALL cell lines by investigating six nutrient transporters (SLCs), identified in our screens (Aim 1). We will obtain mechanistic understanding of the signals, metabolic features, and hematopoietic composition and trajectories, as a function of leukemic Ras-PI3K signals with unprecedented resolution. We will continue efforts on RoLoRiG/Mx1CRE and KRasG12D/Mx1CRE mouse models that display completely opposite phenotypes in bone marrow stem cells (Aim 2). Lastly, we will obtain a comprehensive characterization of developmental-, biochemical- and metabolic- programs in pediatric T-ALL with single cell resolution. We will combine these efforts with preclinical trial to test the in vivo efficacy of PI3Kγ- and δ- inhibition, inhibition of SLC13A2 and SLC25A44, and combinations in our T-ALL/NGS platform (Aim 3). The synergistic aims, metabolic insights, new mouse models, patient sample-NSG pipeline, and innovative, single cell-resolution technology platforms (CyTOF, SCENITH, phospho-flow) will allow us to make significant contributions towards molecular understanding of T-ALL and precision medicine in cancer.

项目总结/文摘